Caseware UK (AP4) 2024.0.164 2024.0.164 2024-12-31 2024-12-31 false 2024-01-01 false Management consultancy activities other than financial management 3 2 true true The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006. 13544632 2024-01-01 2024-12-31 13544632 2023-01-01 2023-12-31 13544632 2024-12-31 13544632 2023-12-31 13544632 c:Director1 2024-01-01 2024-12-31 13544632 d:CurrentFinancialInstruments 2024-12-31 13544632 d:CurrentFinancialInstruments 2023-12-31 13544632 d:CurrentFinancialInstruments d:WithinOneYear 2024-12-31 13544632 d:CurrentFinancialInstruments d:WithinOneYear 2023-12-31 13544632 d:ShareCapital 2024-12-31 13544632 d:ShareCapital 2023-12-31 13544632 d:RetainedEarningsAccumulatedLosses 2024-12-31 13544632 d:RetainedEarningsAccumulatedLosses 2023-12-31 13544632 c:OrdinaryShareClass1 2024-01-01 2024-12-31 13544632 c:OrdinaryShareClass1 2024-12-31 13544632 c:OrdinaryShareClass1 2023-12-31 13544632 c:FRS102 2024-01-01 2024-12-31 13544632 c:AuditExempt-NoAccountantsReport 2024-01-01 2024-12-31 13544632 c:FullAccounts 2024-01-01 2024-12-31 13544632 c:PrivateLimitedCompanyLtd 2024-01-01 2024-12-31 13544632 2 2024-01-01 2024-12-31 13544632 6 2024-01-01 2024-12-31 13544632 e:PoundSterling 2024-01-01 2024-12-31 xbrli:shares iso4217:GBP xbrli:pure

Registered number: 13544632 XMED IQ INTERNATIONAL GROUP LIMITED UNAUDITED DIRECTORS' REPORT AND FINANCIAL STATEMENTS INFORMATION FOR FILING WITH THE REGISTRAR FOR THE YEAR ENDED 31 DECEMBER 2024
XMED IQ INTERNATIONAL GROUP LIMITED REGISTERED NUMBER: 13544632 BALANCE SHEET AS AT 31 DECEMBER 2024
|  | 2024 |  | 2023
Note |  | £ |  | £
Fixed assets |  |  |  |  |
Investments | 4 |  | 7,654 |  | 7,754
|  |  | 7,654 |  | 7,754
Current assets |  |  |  |  |
Debtors: amounts falling due within one year | 5 | 452 |  | 7,285 |
Cash at bank and in hand | 6 | 246 |  | 4,349 |
|  | 698 |  | 11,634 |
Creditors: amounts falling due within one year | 7 | (88,564) |  | (79,539) |
Net current liabilities |  |  | (87,866) |  | (67,905)
Total assets less current liabilities |  |  | (80,212) |  | (60,151)
Net liabilities |  |  | (80,212) |  | (60,151)
Capital and reserves |  |  |  |  |
Called up share capital | 8 |  | 4 |  | 4
Profit and loss account |  |  | (80,216) |  | (60,155)
|  |  | (80,212) |  | (60,151)
Page 1
XMED IQ INTERNATIONAL GROUP LIMITED REGISTERED NUMBER: 13544632 BALANCE SHEET (CONTINUED) AS AT 31 DECEMBER 2024 The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006. The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements. The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities. The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. The Company has opted not to file the statement of comprehensive income in accordance with provisions applicable to companies subject to the small companies' regime. The financial statements were approved and authorised for issue by the board and were signed on its behalf by:
................................................ D Zocholl
Director
Date: 9 January 2026
The notes on pages 3 to 6 form part of these financial statements. Page 2
XMED IQ INTERNATIONAL GROUP LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024
1. | General information
XMED iQ International Group Limited (registered number: 13544632) is a private company, limited by shares, incorporated in the United Kingdom and registered in England and Wales. The company's registered office address is 101 New Cavendish Street, 1st Floor South, London, W1W 6XH. 2.Accounting policies
| 2.1 | Basis of preparation of financial statements
The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the requirements and the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view. The following principal accounting policies have been applied:
| 2.2 | Going concern
In assessing the ability of the company to operate as a going concern, management have evaluated current and forecasted operational results, and the solvency of the company. Given that the company is in a net deficit position, the shareholders have provided assurances to continue to provide adequate funds to meet its obligations, and not to demand repayment of any funds due to them, until the company is in a financial position to do so. As a result, the directors consider it appropriate to prepare the financial statements on a going concern basis.
| 2.3 | Foreign currency translation
Functional and presentation currency The Company's functional and presentational currency is GBP. Transactions and balances Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions. At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined. Foreign exchange gains and losses resulting from the settlement of transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in profit or loss except when deferred in other comprehensive income as qualifying cash flow hedges. Foreign exchange gains and losses that relate to borrowings and cash and cash equivalents are presented in the Statement of Comprehensive Income within 'finance income or costs'. All other foreign exchange gains and losses are presented in profit or loss within 'other operating income'.
| 2.4 | Interest income
Interest income is recognised in profit or loss using the effective interest method. Page 3
XMED IQ INTERNATIONAL GROUP LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024 2.Accounting policies (continued)
| 2.5 | Finance costs
Finance costs are charged to profit or loss over the term of the debt using the effective interest method so that the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.
| 2.6 | Valuation of investments
Investments in subsidiaries are measured at cost less accumulated impairment. Investments in unlisted Company shares, whose market value can be reliably determined, are remeasured to market value at each balance sheet date. Gains and losses on remeasurement are recognised in the Statement of Comprehensive Income for the period. Where market value cannot be reliably determined, such investments are stated at historic cost less impairment. Investments in listed company shares are remeasured to market value at each balance sheet date. Gains and losses on remeasurement are recognised in profit or loss for the period.
| 2.7 | Debtors
Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.
| 2.8 | Cash and cash equivalents
Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.
| 2.9 | Creditors
Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.
3. | Employees
| The average monthly number of employees, including directors, during the year was 3 (2023 - 2).
Page 4
XMED IQ INTERNATIONAL GROUP LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024
4. | Fixed asset investments
|  | Investments in subsidiary companies
|  | £
| Cost or valuation |
| At 1 January 2024 | 7,754
| At 31 December 2024 | 7,754
| Impairment |
| Charge for the period | 100
| At 31 December 2024 | 100
| Net book value |
| At 31 December 2024 | 7,654
| At 31 December 2023 | 7,754
5. | Debtors
|  |  |  |  | 2024 | 2023
|  |  |  |  | £ | £
| Amounts owed by group undertakings | - | 6,096
| Other debtors | 448 | 1,185
| Called up share capital not paid | 4 | 4
|  | 452 | 7,285
6. | Cash and cash equivalents
|  |  |  |  | 2024 | 2023
|  |  |  |  | £ | £
| Cash at bank and in hand | 246 | 4,349
|  | 246 | 4,349
Page 5
XMED IQ INTERNATIONAL GROUP LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024
7. | Creditors: Amounts falling due within one year
|  |  |  |  | 2024 | 2023
|  |  |  |  | £ | £
| Trade creditors | 720 | 961
| Amounts owed to group undertakings | 63,162 | 55,974
| Amounts owed to related parties | 18,277 | 18,203
| Accruals and deferred income | 6,405 | 4,401
|  | 88,564 | 79,539
8. | Share capital
|  |  |  |  | 2024 | 2023
|  |  |  |  | £ | £
|  | Allotted, called up and fully paid |  |
|  | 3,750 (2023 - 3,750) ordinary shares of £0.001 each | 4 | 4
9. | Controlling party
The company is controlled by the directors.
Page 6